Beijing Sun-Novo Pharmaceutical Research News

Sunshine Novo (688621): New orders grew rapidly, Q1 profit side exceeded expectations

國盛證券May 14 02:26

Sunshine Novo (688621): New signings maintain high growth, gross margin continues to rise

長江證券May 13 18:36

Commentary on Sunshine Novo (688621) 2023 Report and 2024 First Quarter Report: Independent R&D Achievements Continue to Advance and Wait for Implementation

國元證券May 11 18:51

Sunshine Novo (688621): New business formats are growing rapidly, and new momentum is ready to be launched

浙商證券May 8 05:16

Sunshine Novo (688621): The profit side exceeded expectations and new orders continued to grow at a high rate in the first quarter

華安證券Apr 29 18:46

Sunshine Novo (688621): Steady growth in performance and abundant orders to ensure future growth

開源證券Apr 29 11:00

Minsheng Securities released a research report on April 27 stating that it gave Sunshine Novo (688621.SH) a recommended rating. The main reasons for the rating include: 1) two-wheel drive for pharmaceutical research and clinical services, continuing to ex

Zhitong FinanceApr 27 19:14

Sunshine Novo (688621): Steady growth in performance, positive implementation of self-research results

東方證券Apr 27 11:00

Sunshine Novo (688621): Profit side growth in Q1 surpassed expectations, strong demand for one-stop CRO business

民生證券Apr 27 00:46

Pacific released a research report on April 26 stating that it gave Sunshine Novo (688621.SH) a purchase rating. The main reasons for the rating include: 1) strong clinical business growth throughout the year, with 23Q4 sales expenses dragging down profit

Zhitong FinanceApr 25 21:49

Sunshine Novo (688621): Performance is basically in line with expectations, and new orders have maintained rapid growth

華西證券Apr 25 11:00

Sunshine Novo (688621) Company Brief Review Report: Generic CRO is rapidly growing, and the layout of self-developed varieties has entered the harvest period

首創證券Mar 13 11:00

Sunshine Novo (688621): Maintaining high revenue growth and gradual implementation of independent research and development

長江證券Mar 4 05:06

Sunshine Novo (688621): The main business continues to grow rapidly and is awaiting independent transformation to bring a second growth curve

中泰證券Feb 26 23:02

Sunshine Novo (688621): Maintaining High Revenue Growth and Entering a Period of Realization of Self-Research Achievements

長江證券Nov 21, 2023 17:32

Sunshine Novo (688621) Company Information Update Report: Continued Outstanding Performance, Transformation of Self-developed New Drugs Opens Up Room for Growth

開源證券Nov 15, 2023 10:00

Sunshine Novo (688621): Performance is in line with expectations, and the main business continues to grow rapidly

中泰證券Nov 5, 2023 10:00

Sunshine Novo (688621): A two-pronged approach between business order sufficiency management model optimization and R&D investment

德邦證券Nov 1, 2023 11:00

Sunshine Novo (688621) Report Review for the Third Quarter of 2023: Independent R&D Achievements Are Rapidly Advancing and Maintaining Annual Results

國元證券Nov 1, 2023 06:02

Novo Sunshine (688621): Steady growth in the third quarter and continued increase in R&D investment

太平洋證券Oct 31, 2023 11:00